Your browser is no longer supported. Please, upgrade your browser.
Entasis Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own0.90% Shs Outstand37.08M Perf Week0.00%
Market Cap66.65M Forward P/E- EPS next Y-1.23 Insider Trans0.00% Shs Float13.35M Perf Month-3.61%
Income-45.90M PEG- EPS next Q-0.36 Inst Own17.40% Short Float2.38% Perf Quarter-44.51%
Sales- P/S- EPS this Y37.00% Inst Trans0.57% Short Ratio1.06 Perf Half Y11.31%
Book/sh1.19 P/B1.57 EPS next Y-16.90% ROA-76.30% Target Price- Perf Year-29.17%
Cash/sh- P/C- EPS next 5Y- ROE-88.30% 52W Range1.58 - 4.25 Perf YTD-24.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.00% Beta-
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low18.35% ATR0.15
Employees47 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)39.44 Volatility7.50% 8.16%
OptionableNo Debt/Eq0.00 EPS Q/Q74.90% Profit Margin- Rel Volume0.78 Prev Close1.87
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume299.67K Price1.87
Recom1.80 SMA20-5.15% SMA50-15.68% SMA200-22.57% Volume105,340 Change0.00%
Sep-09-20Initiated Cantor Fitzgerald Overweight $5
Jul-13-20Initiated ROTH Capital Buy $9
May-05-21 04:05PM  
May-03-21 04:05PM  
Mar-23-21 08:00AM  
Mar-13-21 02:06AM  
Jan-26-21 08:00AM  
Jan-07-21 08:00AM  
Dec-01-20 01:52AM  
Nov-17-20 08:00AM  
Nov-05-20 04:05PM  
Oct-14-20 08:00AM  
Oct-08-20 08:32AM  
Sep-10-20 08:00AM  
Aug-28-20 08:00AM  
Aug-06-20 04:05PM  
Aug-05-20 08:00AM  
Jul-13-20 10:05AM  
Jul-06-20 08:00AM  
Jun-22-20 09:48AM  
Jun-18-20 08:00AM  
Jun-11-20 04:05PM  
May-18-20 11:34AM  
May-07-20 04:05PM  
Apr-22-20 04:05PM  
Mar-13-20 07:46AM  
Mar-11-20 04:05PM  
Dec-19-19 09:49AM  
Nov-24-19 01:56PM  
Nov-14-19 07:30AM  
Oct-30-19 04:05PM  
Oct-29-19 08:30AM  
Oct-03-19 04:01PM  
Oct-01-19 10:07AM  
Sep-30-19 01:00AM  
Sep-19-19 11:56AM  
Sep-03-19 08:00AM  
Aug-12-19 07:30AM  
Aug-06-19 08:00AM  
Jul-01-19 09:13AM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
Jun-20-19 11:13AM  
Jun-18-19 04:01PM  
Jun-13-19 08:00AM  
Jun-10-19 08:00AM  
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Innoviva, Inc.10% OwnerSep 01Buy2.674,672,89712,499,99918,672,897Sep 01 05:31 PM
Innoviva, Inc.10% OwnerJun 11Buy2.5012,677,49031,693,72514,000,000Jun 12 05:34 PM